<DOC>
	<DOC>NCT02484703</DOC>
	<brief_summary>This study will evaluate the safety, tolerability, efficacy, and pharmacokinetic and pharmacodynamic activity of 3 different dosages of RO5186582 compared with placebo. A total of approximately 46 participants will be enrolled, in order to have at least 32 evaluable, and will be randomly assigned to 1 of 4 treatments in a 1:1:1:1 ratio, with 9 children per treatment arm. The target ratio between 6-8 years and 9-11 years age groups is approximately 1:1 in each treatment arm, with a minimum of 3 children per age group in each treatment arm.</brief_summary>
	<brief_title>A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Down Syndrome</mesh_term>
	<criteria>Diagnosis of Down syndrome, except for mosaic Down syndrome Available parent or caregiver to attend clinic visits and provide information about the participant's behavior and symptoms Any primary psychiatric comorbid disorder History of infantile spasms, West syndrome, LennoxGastaut syndrome, early infantile epileptic encephalopathy, treatmentrefractory epilepsy with cognitive/developmental regression, severe head trauma, or central nervous system (CNS) infection Seizure event of any type within 12 months prior to Screening or relevant changes in antiepileptic drugs 6 weeks prior to enrollment Significant sleep disruption Significant gastrointestinal, renal, hepatic, endocrine, or cardiovascular disease Newonset or ongoing hematologic/oncologic disorder Severe lactose intolerance Participation in another clinical study within 1 month or 6 halflives prior to first dose, or any extent of participation in Study BP29589 (NCT02451657)</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>11 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>